TY - JOUR
T1 - A Conceptual Framework for Understanding Unintended Prolonged Opioid Use
AU - Hooten, W. Michael
AU - Brummett, Chad M.
AU - Sullivan, Mark D.
AU - Goesling, Jenna
AU - Tilburt, Jon C.
AU - Merlin, Jessica S.
AU - St. Sauver, Jennifer L.
AU - Wasan, Ajay D.
AU - Clauw, Daniel J.
AU - Warner, David O.
N1 - Funding Information:
Potential Competing Interests: Dr Hooten is a member of a scientific advisory board for Chrono Therapeutics. Dr Brummett serves as a consultant to Tonix; receives research funding from Neuros Medical Inc, the National Institutes of Health, and UM Michigan Genomics Initiative; and has a patent for peripheral perineural dexmedetomidine. Dr Sullivan is a consultant for Chrono Therapeutics; is an employee of the University of Washington; has provided expert testimony for Johns Hopkins University; receives research support from Pfizer; and receives royalties from Oxford University Press. Dr St. Sauver receives research support from the National Institute on Aging. Dr Wasan serves as a consultant to Egalet Pharmaceuticals, Cara Therapeutics, and Analgesic Solutions. Dr Clauw is a member of a scientific advisory board for Abbott, Astellas, Cerephex, Pfizer, and Zynerba; has received consulting fees from Aptinyx, Daiichi Sankyo, Pfizer, Cerephex, Tonix, Abbott, Sammumed, and Therevance; is an employee of the University of Michigan; has provided expert testimony for Pfizer and Williams & Connolly LLP; and has received research support from the National Institutes of Health, Aptinyx, Pfizer, and Cerephex. Dr Warner is a member of a scientific advisory board for the American Board of Anesthesiology; is an employee of Mayo Clinic; and receives research support from the National Institutes of Health.
Publisher Copyright:
© 2017 Mayo Foundation for Medical Education and Research
Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 2017/12
Y1 - 2017/12
N2 - An urgent need exists to better understand the transition from short-term opioid use to unintended prolonged opioid use (UPOU). The purpose of this work is to propose a conceptual framework for understanding UPOU that posits the influence of 3 principal domains that include the characteristics of (1) individual patients, (2) the practice environment, and (3) opioid prescribers. Although no standardized method exists for developing a conceptual framework, the process often involves identifying corroborative evidence, leveraging expert opinion to identify factors for inclusion in the framework, and developing a graphic depiction of the relationships between the various factors and the clinical problem of interest. Key patient characteristics potentially associated with UPOU include (1) medical and mental health conditions; (2) pain etiology; (3) individual affective, behavioral, and neurophysiologic reactions to pain and opioids; and (4) sociodemographic factors. Also, UPOU could be influenced by structural and health care policy factors: (1) the practice environment, including the roles of prescribing clinicians, adoption of relevant practice guidelines, and clinician incentives or disincentives, and (2) the regulatory environment. Finally, characteristics inherent to clinicians that could influence prescribing practices include (1) training in pain management and opioid use; (2) personal attitudes, knowledge, and beliefs regarding the risks and benefits of opioids; and (3) professionalism. As the gatekeeper to opioid access, the behavior of prescribing clinicians directly mediates UPOU, with the 3 domains interacting to determine this behavior. This proposed conceptual framework could guide future research on the topic and allow plausible hypothesis-based interventions to reduce UPOU.
AB - An urgent need exists to better understand the transition from short-term opioid use to unintended prolonged opioid use (UPOU). The purpose of this work is to propose a conceptual framework for understanding UPOU that posits the influence of 3 principal domains that include the characteristics of (1) individual patients, (2) the practice environment, and (3) opioid prescribers. Although no standardized method exists for developing a conceptual framework, the process often involves identifying corroborative evidence, leveraging expert opinion to identify factors for inclusion in the framework, and developing a graphic depiction of the relationships between the various factors and the clinical problem of interest. Key patient characteristics potentially associated with UPOU include (1) medical and mental health conditions; (2) pain etiology; (3) individual affective, behavioral, and neurophysiologic reactions to pain and opioids; and (4) sociodemographic factors. Also, UPOU could be influenced by structural and health care policy factors: (1) the practice environment, including the roles of prescribing clinicians, adoption of relevant practice guidelines, and clinician incentives or disincentives, and (2) the regulatory environment. Finally, characteristics inherent to clinicians that could influence prescribing practices include (1) training in pain management and opioid use; (2) personal attitudes, knowledge, and beliefs regarding the risks and benefits of opioids; and (3) professionalism. As the gatekeeper to opioid access, the behavior of prescribing clinicians directly mediates UPOU, with the 3 domains interacting to determine this behavior. This proposed conceptual framework could guide future research on the topic and allow plausible hypothesis-based interventions to reduce UPOU.
UR - http://www.scopus.com/inward/record.url?scp=85032958992&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85032958992&partnerID=8YFLogxK
U2 - 10.1016/j.mayocp.2017.10.010
DO - 10.1016/j.mayocp.2017.10.010
M3 - Article
C2 - 29108841
AN - SCOPUS:85032958992
SN - 0025-6196
VL - 92
SP - 1822
EP - 1830
JO - Mayo Clinic Proceedings
JF - Mayo Clinic Proceedings
IS - 12
ER -